• Citer

Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer

par Denys, Hannelore;Martinez-Mena, Corina ;Martens, Marc;D’Hondt, Randal R.G.;Graas, Marie-Pascale;Evron, Ella;Fried, Georgeta;Ben-Baruch, Noa Efrat;Vulsteke, Christof;Van Steenberghe, Mona M.M.
Référence Breast cancer research and treatment
Publication Publié, 2020

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Safety and tolerability of subcutaneous trastuzumab at home administration, results of the phase IIIb open-label BELIS study in HER2-positive early breast cancer
Auteur:	Denys, Hannelore; Martinez-Mena, Corina; Martens, Marc; D’Hondt, Randal R.G.; Graas, Marie-Pascale; Evron, Ella; Fried, Georgeta; Ben-Baruch, Noa Efrat; Vulsteke, Christof; Van Steenberghe, Mona M.M.
Informations sur la publication:	Breast cancer research and treatment
Statut de publication:	Publié, 2020
Sujet CREF:	Cancérologie
Mots-clés:	At home administration
	HER2-positive early breast cancer
	Safety
	Subcutaneous trastuzumab
	Tolerability
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:0167-6806
	info:doi/10.1007/s10549-020-05604-7
	info:scp/85082814745